{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061631","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.448817+00:00","generated_at":"2026-06-01T23:28:55.853743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility","bullets":["Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.","Net loss available to common stockholders was $13.2M ($0.60 per share) vs $8.3M loss in Q1 2023.","Closed $25M initial draw on up to $50M debt financing with OrbiMed; expects runway through end of 2024.","Appointed Liselotte Hyveled, Chief Patient Officer at Novo Nordisk, to Board of Directors.","Management reiterates full-year revenue growth guidance exceeding 50%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061631","json":"https://secwatch.observer/filing/0001104659-24-061631.json","markdown":"https://secwatch.observer/filing/0001104659-24-061631.md","text":"https://secwatch.observer/filing/0001104659-24-061631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/0001104659-24-061631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/tm2414537d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:28:55.853743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ee02926d15c2949fda229f105bb3a3e1a8ef7ee","claim":"TriSalus Life Sciences, Inc. reported first quarter ended March 31, 2024 results: revenue $6.5 million, net income $13.2 million, EPS $0.60.","evidence_excerpt":"TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/0001104659-24-061631-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.5 million"},{"label":"Net income","value":"$13.2 million"},{"label":"EPS","value":"$0.60"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}